From time to time, the Company grants stock options and restricted stock units (“RSUs”) to its employees, including the named executive officers. Historically, the Company has granted new-hire option awards on or soon after a new hire’s employment start date and annual refresh employee option grants in the second quarter of each fiscal year, which refresh grants are typically approved at the regularly scheduled meeting of the Compensation Committee and the Board occurring in such quarter. Also, non-employee directors receive automatic grants of initial and annual stock option awards, at the time of a director’s initial appointment or election to the Board and at the time of each annual meeting of the Company’s stockholders, respectively, pursuant to the non-employee director compensation policy described above. The Company does not otherwise maintain any written policies on the timing of awards of stock options, stock appreciation rights, or similar instruments with option-like features. The Compensation Committee and the Board consider whether there is any material nonpublic information about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to the Company’s public disclosure of material nonpublic information. The Company has not timed the release of material nonpublic information for the purpose of affecting the value of executive compensation.

The following table is being provided pursuant to Item 402(x)(2) of Regulation S-K.

Percentage change in the closing

market price of the securities

underlying the award between

the trading day ending

immediately prior to the

disclosure of material nonpublic

information and the trading day

beginning immediately following

Number of securities

Exercise price of the

Grant date fair

the disclosure of material

Name

Grant date

underlying the award

award ($/Sh)

value of the award

nonpublic information

(a)

(b)

(c)

(d)

(e)

(f)

Malte Peters

June 17, 2024

4,900

⁽¹⁾

$

7.10

$

28,486

(7.9)

%

Terry Coelho

June 17, 2024

4,900

⁽¹⁾

$

7.10

$

28,486

(7.9)

%

(1)

These awards were made one business day before the Company filed a Current Report on Form 8-K reporting the results the Company’s 2024 annual meeting of stockholders. The award was made pursuant to the Company’s non-employee director compensation policy providing for the annual grant of options to each continuing non-employee member of the Board of Directors at the time of the Company’s annual meeting. Dr. Peters and Ms. Coelho were named our Chief Executive Officer and President and our Executive Vice President and Chief Financial Officer, respectively, effective July 22, 2024.

Award Timing Predetermined

true

Award Timing, How MNPI Considered

The Compensation Committee and the Board consider whether there is any material nonpublic information about the Company when determining the timing of stock option grants and does not seek to time the award of stock options in relation to the Company’s public disclosure of material nonpublic information. The Company has not timed the release of material nonpublic information for the purpose of affecting the value of executive compensation.

Awards Close in Time to MNPI Disclosures, Table

The following table is being provided pursuant to Item 402(x)(2) of Regulation S-K.

Percentage change in the closing

market price of the securities

underlying the award between

the trading day ending

immediately prior to the

disclosure of material nonpublic

information and the trading day

beginning immediately following

Number of securities

Exercise price of the

Grant date fair

the disclosure of material

Name

Grant date

underlying the award

award ($/Sh)

value of the award

nonpublic information

(a)

(b)

(c)

(d)

(e)

(f)

Malte Peters

June 17, 2024

4,900

⁽¹⁾

$

7.10

$

28,486

(7.9)

%

Terry Coelho

June 17, 2024

4,900

⁽¹⁾

$

7.10

$

28,486

(7.9)

%

(1)

These awards were made one business day before the Company filed a Current Report on Form 8-K reporting the results the Company’s 2024 annual meeting of stockholders. The award was made pursuant to the Company’s non-employee director compensation policy providing for the annual grant of options to each continuing non-employee member of the Board of Directors at the time of the Company’s annual meeting. Dr. Peters and Ms. Coelho were named our Chief Executive Officer and President and our Executive Vice President and Chief Financial Officer, respectively, effective July 22, 2024.

Awards Close in Time to MNPI Disclosures

Underlying Securities

4,900

Fair Value as of Grant Date | $

$ 28,486

Name

Terry Coelho

Exercise Price | $ / shares

$ 7.1

Underlying Security Market Price Change

(7.9)

HOOKIPA Pharma Inc. 10-K/A